Tonix Pharmaceuticals Holding (TNXP) Accumulated Depreciation (2017 - 2026)

Tonix Pharmaceuticals Holding's Accumulated Depreciation history runs 10 years deep, the most recent figure standing at $6.6 million for Q1 2026.

• On a quarterly basis, Accumulated Depreciation rose 43.29% year-over-year to $6.6 million in Q1 2026; TTM through Mar 2026 was $6.6 million, a 43.29% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, up 46.99% from the prior year.
• Accumulated Depreciation grew to $6.6 million in Q1 2026 per TNXP's latest filing, from $6.0 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $6.6 million in Q1 2026 and bottomed at $463000.0 in Q1 2022.
• The 5-year median for Accumulated Depreciation is $4.1 million (2024), against an average of $3.8 million.
• Across the five-year window, Accumulated Depreciation surged 513.63% in 2023 and fell 27.53% in 2025, its largest moves.
• Year by year, Accumulated Depreciation stood at $1.7 million in 2022, then soared by 224.38% to $5.4 million in 2023, then fell by 23.59% to $4.1 million in 2024, then soared by 46.99% to $6.0 million in 2025, then rose by 9.22% to $6.6 million in 2026.
• Per Business Quant, the three latest TNXP Accumulated Depreciation figures stand at $6.6 million (Q1 2026), $6.0 million (Q4 2025), and $5.5 million (Q3 2025).